Learning from clinical trials of neoadjuvant checkpoint blockade

Versluis, J.M.; Long, G.V.; Blank, C.U. (2020)

Article / Letter to editor

Neoadjuvant checkpoint inhibition, in which the therapy is administered before surgery, is a promising new approach to managing bulky but resectable melanoma, and is also being explored in other cancers. This strategy has a high pathologic response rate, which correlates with survival outcomes. The fact that biopsies are routinely available provides a unique opportunity for understanding the responses to therapy and carrying out reverse translation in which these data are used to select therapies in the clinic or in trials that are more likely to improve patient outcomes. In this Perspective, we discuss the rationale for neoadjuvant immunotherapy in resectable solid tumors based on preclinical and human translational data, summarize the results of recent clinical trials and ongoing research, and focus on future directions for enhancing reverse translation.

• All authors: Versluis, J.M.; Long, G.V.; Blank, C.U.
• Date: 2020
• Journal: Nature Medicine
• Volume: 26
• Issue: 4
• Pages: 475 - 484
• DOI: doi:10.1038/s41591-020-0829-0
• Link: https://www.nature.com/articles/s41591-020-0829-0